Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Te...( Centerpiece of the agreement is the e...)

Centerpiece of the agreement is the establishment of The Waters Centre for BioMedical Mass Spectrometry

MILFORD, Mass., April 15 /PRNewswire/ -- Waters Corporation (NYSE: WAT) and the University of Warwick, Coventry and Warwickshire, England, today signed a collaborative research agreement intended to support the growth, development and adoption of novel mass spectrometry (MS) technologies, including Waters(R) SYNAPT High Definition MS(TM) (HDMS(TM)) system. This agreement paves the way for research projects leading to meaningful impact for analysts using biomedical mass spectrometry, validated by peer-reviewed publications, presentations at international conferences and an outreach education program.

At the core of the collaborative agreement is the establishment of 'The Waters Centre for BioMedical Mass Spectrometry' at the University of Warwick, a center of excellence in state-of-the-art MS techniques. This center will offer scientists worldwide an accessible resource to enable the adoption of cutting edge LC/MS-based techniques in life science.

"I believe that this partnership between a proven technology leader and a leading research focused University will provide a platform for the development of many exciting new projects," said Prof. James Scrivens, Department of Biological Sciences, University of Warwick. "I look forward to being part of a team that delivers the benefits of our research to the wider community."

"The University of Warwick is consistently ranked amongst the top research universities, with an historic track record in biological mass spectrometry," said Brian Smith, Vice President, Mass Spectrometry Operations for the Waters Division. "However, this agreement is not based on reputation alone; it is based on a
'/>"/>